Geographic Atrophy

• CLINICAL_TRIALS research · 2025-06-26
  Clinical Trial Update: A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating the oral agent BRX011 for geographic atrophy due to age-related macular degeneration; the study is not…

• CLINICAL_TRIALS research · 2025-06-13
  Clinical Trial Update: Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

  An ongoing natural history study (i-GAIN) on geographic atrophy in dry age-related macular degeneration is active but not recruiting. The st…

• CLINICAL_TRIALS trial_result · 2025-06-11
  Clinical Trial Update: COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy [NA]

  A completed clinical trial comparing Clarus and Optos ultrawide-field imaging systems for geographic atrophy in age-related macular degenera…

• CLINICAL_TRIALS research · 2025-05-15
  Clinical Trial Update: Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression

  A clinical trial update from the Medical University of Vienna describes a study evaluating AI-assisted personalized monitoring of non-foveal…

• CLINICAL_TRIALS trial_result · 2025-05-01
  Clinical Trial Update: Patients With Geographic Atrophy and Their Patient Journey in the United States (US)

  A completed US clinical trial examining the patient journey for geographic atrophy, with results posted in May 2025.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2025-04-22
  Clinical Trial Update: High Resolution Retinal Imaging

  A University of Pennsylvania-sponsored clinical trial using high-resolution retinal imaging is currently recruiting participants for several…

• CLINICAL_TRIALS trial_result · 2025-04-16
  Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). [Phase 2]

  A Phase 2 trial evaluating oral CT1812 in geographic atrophy secondary to dry age-related macular degeneration has been terminated; no effic…

• CLINICAL_TRIALS research · 2025-03-24
  Clinical Trial Update: A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

  A prospective observational study to assess the reliability and validity of the MLSDT for macular degeneration-related conditions, currently…

• CLINICAL_TRIALS trial_result · 2025-03-07
  Clinical Trial Update: GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) [Phase 2]

  Phase 2 study to assess safety and efficacy of multiple doses of IONIS-FB-LRx in geographic atrophy due to age-related macular degeneration;…

• CLINICAL_TRIALS trial_result · 2025-03-06
  Clinical Trial Update: The GA in HSI Study

  A completed clinical trial update from Optina Diagnostics for the GA in HSI study investigating geographic atrophy. The listed condition is …

• CLINICAL_TRIALS trial_result · 2025-02-19
  Clinical Trial Update: Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study

  A completed clinical trial evaluating optical coherence tomography and microperimetry biomarkers in geographic atrophy due to age-related ma…

• CLINICAL_TRIALS trial_result · 2025-02-18
  Clinical Trial Update: A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy [Phase 1]

  Phase 1 study evaluating tolerability of escalating doses of BI 771716 in people with geographic atrophy, an advanced form of age-related ma…

• FDA approval · 2025-02-12
  FDA Approved: IZERVAY — Supplemental Application (Astellas Pharma US, Inc.)

  The FDA approved a supplemental application for IZERVAY (avacincaptad pegol) submitted by Astellas Pharma US, Inc.

• EMA withdrawal · 2025-02-04
  EMA Application withdrawn: Izelvay (avacincaptad pegol) — Astellas Pharma Europe B.V.

  EMA has withdrawn the marketing authorization application for Izelvay (avacincaptad pegol) submitted by Astellas Pharma Europe B.V. for geog…

• CLINICAL_TRIALS withdrawal · 2025-02-03
  Clinical Trial Update: Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) [Phase 2]

  Phase 2 trial evaluating CNTO 2476 for visual acuity impairment due to geographic atrophy from age-related macular degeneration has been wit…

• CLINICAL_TRIALS research · 2025-01-08
  Clinical Trial Update: Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

  This clinical trial update describes an observational study to assess endpoint feasibility and measurement properties in patients with retin…

• FDA approval · 2024-12-20
  FDA Approved: SYFOVRE — Supplemental Application (Apellis Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for SYFOVRE (pegcetacoplan) from Apellis Pharmaceuticals.

• CLINICAL_TRIALS research · 2024-12-03
  Clinical Trial Update: Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD [NA]

  A multicenter clinical study investigating SING-IMT for late-stage age-related macular degeneration, including geographic atrophy, is curren…

• CLINICAL_TRIALS research · 2024-11-29
  Clinical Trial Update: Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD [NA]

  Update on a clinical trial evaluating the PRIMA System to restore central vision in geographic atrophy due to age-related macular degenerati…

• CLINICAL_TRIALS trial_result · 2024-11-19
  Clinical Trial Update: ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration [Phase 1]

  Phase 1 study of ONL1204 Ophthalmic Solution for geographic atrophy associated with age-related macular degeneration has completed.

• CLINICAL_TRIALS trial_result · 2024-10-30
  Clinical Trial Update: GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  A clinical trial evaluating the natural progression of dry age-related macular degeneration (AMD) sponsored by Gyroscope Therapeutics Limite…

• CLINICAL_TRIALS research · 2024-09-24
  Clinical Trial Update: Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration. [Phase 1, Phase 2]

  This clinical trial update notes that Eyestem Research's Eyecyte-RPE is currently recruiting Phase 1/2 participants to evaluate safety and e…

• CLINICAL_TRIALS trial_result · 2024-08-21
  Clinical Trial Update: A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy [Phase 2]

  A Phase 2 clinical trial evaluating the efficacy and safety of intravitreal ANX007 in geographic atrophy has completed.

• CLINICAL_TRIALS trial_result · 2024-07-12
  Clinical Trial Update: Geographic Atrophy Long-Terms Outcomes Study

  Apellis Pharmaceuticals reports that the Geographic Atrophy Long-Term Outcomes Study has completed, providing long-term data related to geog…

• CLINICAL_TRIALS trial_result · 2024-04-11
  Clinical Trial Update: Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration [Phase 1, Phase 2]

  Phase 1/2 clinical trial update for VOY-101 in advanced non-neovascular age-related macular degeneration and geographic atrophy.